Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Plastic mulch, basically thin sheeting placed over individual crops, is used throughout China's arid and dusty north to improve growing conditions and boost yields by retaining moisture for crops and suppressing weeds. The country deploys about 200,000 square km (77,220 square miles) of plastic mulch, an area the size of Belarus. A notice published by several ministries on Wednesday said China would work to improve the recovery rate of plastic mulch to 80% next year and ensure there is "zero growth" in the amount of plastic mulch used. It will aim to bring recovery rates to 100% and start reducing total land coverage by 2025. The notice said China would also work to improve its monitoring capability and include mulch pollution in the performance indicators of local government officials. Manufacturers will also be put under pressure to improve product standards. China uses about 2 million to 3 million tonnes of plastic mulch every year, but waste treatment capacity amounts to just 180,000 tonnes, Yan Changrong, a researcher with the China Rural Science Institute, said at a recent forum. While the use of plastic film can boost yields significantly in the short term, unrecovered remnants eventually degrade the soil and can also contaminate crops, with Chinese exports of spinach and ginger found to contain traces of plastic, said Xu Jingeng, a parliamentary delegate for Shandong province, in a proposal submitted to the National People's Congress in March. Handling large volumes of plastic waste has become one of China's pressing challenges. The country's recycling capacity stands at around 23 million to 25 million tonnes, only half of total annual plastic waste produced, according to data from the Beijing Chemistry University. The city of Shanghai is gradually restricting the use of single-use plastics in catering, and the island province of Hainan has already vowed to completely eliminate single-use plastic by 2025. [nL4N23Y1YE][nL3N20G7K1] Claim: China vows to raise recycling rates of rural plastic mulch.

Output: China vowed to improve the recycling rates of plastic mulch used in farming, the government said on Wednesday, amid mounting concerns about soil contamination as unrecovered bits of the thin film get left behind, leaving traces in crops.

Input: Consider Input: Paragraph: Given that the premise of the story is explaining there is no benefit to taking these supplements, we'll rate this N/A. That said, it would have been interesting to explore the cost-savings for people if they decide to stop buying calcium and vitamin D. The story does a good job of letting readers know that there was no statistically significant benefit to taking calcium and vitamin D, based on the researchers' systematic review of the evidence. The story cited one instance of harms, saying: "for people who started out with at least 20 nanograms of vitamin D per milliliter of blood, adding more vitamin D through supplements was associated with a greater risk of hip fractures." We also wanted to see a mention of potential harms of calcium, such as kidney stones. Another common side effect is excess gas and one potential harm of high doses is cardiovascular complications such as heart attack. The story hits some key points including the number of studies reviewed, potential confounding factors accounted for, and details about selection criteria. For instance, women on hormone replacement therapy, for whom there's evidence for the benefits of supplementation were excluded from the current analysis. That's a key point for postmenopausal women reading the story. Also the story makes clear that this study examined older adults who live in their own homes and therefore does not apply to older adults who live in nursing homes or similar institutions. Well done. The story does not engage in disease-mongering. It correctly states the risk of broken bones in people over age 50 and the risk of death in older people who break a hip. This story will also help reduce over-treatment and over-medicating of older adults, which is common. The only source quoted for the article is the study itself. There are no quotes from independent expert sources. The story references getting calcium from one's diet and getting vitamin D from sun exposure. We think it's safe to presume that readers know that vitamin and mineral supplements are widely available. The story does a good job of making clear previous claims of benefit from calcium and vitamin D supplementation. This large meta-analysis will provide some clarity of the questions surrounding using these supplements for bone health. The story does not appear to rely on a news release. Claim: Do you take calcium and vitamin D to protect your bones? A new study says it doesn't help

Output: Getty Images Reporting on a large review study, this Los Angeles Times article walks readers through the conflicting advice and evidence about calcium and vitamin D supplements. Both compounds play roles in bone health and the routinely accepted claim is that supplementation can help prevent bone breaks in older people. This new meta-analysis shows that claim is not supported by evidence: not for calcium pills, vitamin D pills, or the two in combination. The story is well-done on several points, particularly on explaining how this study worked and what it found. The story would have been stronger if it had included some commentary from experts in the field who were not associated with the study to help put this recent, apparently strong finding, into context for readers. More than two million so-called fragility fractures breaks that wouldn't happen in a younger person, often related to the bone loss of osteoporosisoccur every year in the US. Preventing fragility means attending to bone health, which currently centers around exercise and getting enough calcium and vitamin D. Supplementation is an easy way to make sure a person takes in enough of the mineral and the vitamin, and yet, it's important to understand whether routine supplementation actually prevents bone breaks.

Input: Consider Input: Paragraph: Lexicon shares, which have lost about 15 percent of their value last year, fell as much as 7.5 percent to $1.85 on the Nasdaq in early trading on Monday. The company said Arthur Sands, CEO since 1995 and a co-founder, intends to develop a succession plan with the board. He will continue in his position until a successor is appointed. Analysts said Sands might have been perceived as more of a scientist who would not be able to lead the company into a commercial launch of the late-stage drugs. "I think Arthur Sands could have easily done the transition to commercial, but possibly the board felt they wanted someone with direct commercial experience", Wedbush analyst Liana Moussatos said. Lexicon said it would cut 115 jobs, primarily positions in research and discovery, to reduce costs. The company said it would focus mainly on its drugs to treat diabetes and carcinoid syndrome, a condition which affects some people with a rare cancerous tumor. "Most of the value of the company is wrapped up in these late-stage drugs," Morningstar analyst Karen Andersen said. "It makes sense to focus on what investors are really looking at." Lexicon said it expects to lower expenses by about $14 million, net of severance costs and some other charges, for the rest of 2014. It expects to save about $22 million annually. "This could give them an extra two to three quarters of cash," Moussatos said. The company had $151.2 million in cash and investments as of September 30 last year. Andersen said Lexicon needed to conserve cash while it looked for a partner to fund the development of its diabetes drug. "In order to do a comprehensive diabetes program, it takes hundreds of millions of dollars, which is more than Lexicon can afford right now," she said. The company is testing two other drugs in mid-stage trials to treat irritable bowel syndrome and rheumatoid arthritis. It also has a glaucoma drug in early-stage development. Moussatos said that Lexicon could license the development of the drugs to other pharmaceutical companies. Lexicon has drug discovery agreements with Bristol-Myers Squibb Co, Roche Holding AG's unit Genentech and Takeda Pharmaceutical Co Ltd. Lexicon shares, which once traded above $40, were down 4.5 percent at $1.91. Claim: Lexicon Pharma to cut 45 percent of workforce, CEO to leave.
Output: Lexicon Pharmaceuticals Inc said its chief executive would leave and it would cut its workforce by about 45 percent, as it moves its focus away from drug discovery to completing the studies of its drugs in late-stage development.